Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

84 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study): primary analysis.
Tanaka H, Tanzawa S, Misumi T, Makiguchi T, Inaba M, Honda T, Nakamura J, Inoue K, Kishikawa T, Nakashima M, Fujiwara K, Kohyama T, Ishida H, Kuyama S, Miyazawa N, Nakamura T, Miyawaki H, Oda N, Ishikawa N, Morinaga R, Kusaka K, Fujimoto N, Fukuda Y, Yasugi M, Tsuda T, Ushijima S, Shibata K, Shibayama T, Bessho A, Kaira K, Shiraishi K, Matsutani N, Seki N. Tanaka H, et al. Among authors: bessho a. Ther Adv Med Oncol. 2022 Dec 18;14:17588359221142786. doi: 10.1177/17588359221142786. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 36570411 Free PMC article.
Triple combination chemotherapy with cisplatin, docetaxel, and irinotecan for advanced non-small cell lung cancer: a phase I/II trial.
Kiura K, Takigawa N, Segawa Y, Tabata M, Shibayama T, Gemba K, Bessho A, Fujimoto N, Takata I, Hotta K, Fujiwara K, Tokuda Y, Kuyama S, Shinkai T, Ueoka H, Tanimoto M; Okayama Lung Cancer Study Group. Kiura K, et al. Among authors: bessho a. J Thorac Oncol. 2007 Jan;2(1):44-50. doi: 10.1097/JTO.0b013e31802bafe2. J Thorac Oncol. 2007. PMID: 17410009 Free article. Clinical Trial.
A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.
Yoshioka H, Hotta K, Kiura K, Takigawa N, Hayashi H, Harita S, Kuyama S, Segawa Y, Kamei H, Umemura S, Bessho A, Tabata M, Tanimoto M; Okayama Lung Cancer Study Group. Yoshioka H, et al. Among authors: bessho a. J Thorac Oncol. 2010 Jan;5(1):99-104. doi: 10.1097/JTO.0b013e3181c20063. J Thorac Oncol. 2010. PMID: 19898258 Free article. Clinical Trial.
Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience.
Hotta K, Kiura K, Takigawa N, Yoshioka H, Harita S, Kuyama S, Yonei T, Fujiwara K, Maeda T, Aoe K, Ueoka H, Kamei H, Umemura S, Moritaka T, Segawa Y, Kawai H, Bessho A, Kato K, Tabata M, Tanimoto M. Hotta K, et al. Among authors: bessho a. J Thorac Oncol. 2010 Feb;5(2):179-84. doi: 10.1097/JTO.0b013e3181ca12e0. J Thorac Oncol. 2010. PMID: 20101144 Free article.
Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001.
Ichihara E, Hotta K, Nogami N, Kuyama S, Kishino D, Fujii M, Kozuki T, Tabata M, Harada D, Chikamori K, Aoe K, Ueoka H, Hosokawa S, Bessho A, Hisamoto-Sato A, Kubo T, Oze I, Takigawa N, Tanimoto M, Kiura K. Ichihara E, et al. Among authors: bessho a. J Thorac Oncol. 2015 Mar;10(3):486-91. doi: 10.1097/JTO.0000000000000434. J Thorac Oncol. 2015. PMID: 25695221 Free article. Clinical Trial.
Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases.
Isozaki H, Ichihara E, Takigawa N, Ohashi K, Ochi N, Yasugi M, Ninomiya T, Yamane H, Hotta K, Sakai K, Matsumoto K, Hosokawa S, Bessho A, Sendo T, Tanimoto M, Kiura K. Isozaki H, et al. Among authors: bessho a. Cancer Res. 2016 Mar 15;76(6):1506-16. doi: 10.1158/0008-5472.CAN-15-1010. Epub 2015 Dec 30. Cancer Res. 2016. PMID: 26719536
Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience.
Kudo K, Hotta K, Bessho A, Nogami N, Kozuki T, Kuyama S, Inoue K, Harita S, Okada T, Gemba K, Fujii M, Takigawa N, Oda N, Tanimoto M, Kiura K. Kudo K, et al. Among authors: bessho a. Cancer Chemother Pharmacol. 2016 May;77(5):1005-9. doi: 10.1007/s00280-015-2910-9. Epub 2016 Mar 31. Cancer Chemother Pharmacol. 2016. PMID: 27029623
84 results